Skip to main content
. 2015 Dec 22;15(3):455–470. doi: 10.1080/15384101.2015.1127478

Figure 1.

Figure 1.

ARTIK-52 treatment leads to the reduction of AR and ERBB2 levels. A, B. Western blotting of protein extracts of CWR22R, LNCaP and C4-2 cells treated with 1 μM of ARTIK-52 for different periods of time (A) or with different concentrations for 24 hours (B) stained with AR and β-actin antibodies. Solid arrow marks full length 110 kDa form of AR, dashed arrow marks 80kDa AR isoform lacking ligand binding domain in CWR22R cells. C, D. Normalized data of qPCR with reversed transcribed total RNA of CWR22R cells treated with 1 μM of ARTIK-52 for different periods of time (C) or with different concentrations for 24 hours (D). Error bars represent standard deviation between 3 replicates within one experiment. E. Western blotting of protein extracts of LNCaP and MCF7 cells treated with ARTIK-52 for 24 hours stained with ERBB2 and β-actin antibodies.